Arcturus Therapeutics Holdings Inc. (ARCT) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$9.89

From 52W high−35.79%

Volume495762.00

Market cap$308.96M

P/E (TTM)—

P/S (TTM)13.0x

Div yield—

Key dataNov 4, 2026

Open

$9.89

From 52W high

−35.79%

Volume

495762.00

Market cap

$308.96M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.7x

P/E (TTM)

—

RSI (14)

41.9

MomentumView details →

1D Return

+13.94%

YTD Return

+65.09%

SummaryUpdated Jun 1, 2026

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a biotechnology company founded in 2013 and headquartered in San Diego, California. The company specializes in developing RNA-based medicines, focusing on vaccines for infectious diseases and therapeutic treatments for rare genetic disorders affecting the liver and respiratory system. Since going public in 2013, Arcturus has evolved from an early-stage biotech into a clinical-stage company with multiple programs in human trials and its first approved product - a COVID-19 vaccine launched in Japan.

Ask drillr about Arcturus Therapeutics Holdings Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.7x

EV/Sales

5.9x

P/S (TTM)

13.0x

P/B (TTM)

1.8x

ProfitabilityView details →

Gross Margin

83.19%

Net Margin

−391.90%

EBITDA Margin

−345.67%

ROE (TTM)

−54.29%

ROA (TTM)

−41.58%

Asset Turnover

0.10x

GrowthView details →

Revenue YoY

−79.07%

EPS YoY

−49.33%

FCF YoY

−12.11%

Revenue CAGR 3Y

−31.13%

EPS CAGR 3Y

+20.00%

EBITDA YoY

−44.16%

MomentumView details →

1D Return

+13.94%

YTD Return

+65.09%

1Y Return

+17.13%

RSI (14)

41.9

vs 50D SMA

−24.08%

vs 200D SMA

+11.99%

Capital & dividendView details →

Debt/Equity

0.13x

Current Ratio

5.88x

Quick Ratio

5.88x

Div Yield

—

Div Rate

—

Div Growth 1Y

−78.71%

EarningsView details →

EPS (Actual)

−$0.84

EPS Surprise

15.70%

Beats (12Q)

7/12

Next Q EPS Est

−$0.91

Avg Surprise (4Q)

−56.67%

Rev Surprise

−4.78%

Financials snapshotView financials →

Revenue (TTM)

23.80M

Net Income (TTM)

−93.28M

Op. CF (TTM)

−72.73M

Next earningsNov 5, 2026 →

Latest newsMore news →

Arcturus Therapeutics announced that it will release its third-quarter 2026 financial results after market close and host a conference call and webcast on November 5, 2026.9d ago

Arcturus Therapeutics announced encouraging interim Phase 2 results for ARCT-810 in ornithine transcarbamylase (OTC) deficiency and introduced its next-generation mRNA delivery platform LUNAR 2.0 along with additional liver pipeline programs.42d ago

Similar companies

Cypherpunk Technologies Inc.CYPH Enanta Pharmaceuticals, Inc.ENTA Transcenta Holding Limited06628.HK ARS Pharmaceuticals, Inc.SPRY Agenus Inc.AGEN Century Therapeutics, Inc.IPSC Find similar companies →

Latest newsMore news →

Arcturus Therapeutics announced that it will release its third-quarter 2026 financial results after market close and host a conference call and webcast on November 5, 2026.9d ago Arcturus Therapeutics announced encouraging interim Phase 2 results for ARCT-810 in ornithine transcarbamylase (OTC) deficiency and introduced its next-generation mRNA delivery platform LUNAR 2.0 along with additional liver pipeline programs.42d ago Arcturus Therapeutics announced it will host a virtual presentation on September 23, 2026, to provide an overview of the ARCT-810 Phase 2 clinical program for Ornithine transcarbamylase (OTC) deficiency and its mRNA liver therapeutics platform.47d ago